Study guide

4.4 Stem Cell Enumeration & ISHAGE Protocol

ASCP SCYM Specialist in Cytometry Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Flow Cytometry Instrumentation & Biophysics

1.1 Fluidic Systems: Hydrodynamic Focusing, Acoustic Focusing, Laminar Flow & Sheath Dynamics 1.2 Laser Physics, Light Sources & Beam Shaping Optics 1.3 Optical Layout: Dichroic Mirrors, Bandpass Filters & Spatial Separation 1.4 Photo Detectors: PMTs, APDs, Silicon Photomultipliers & Spectral Arrays 1.5 Signal Processing, Pulse Geometry & Preamplifiers 1.6 Analog-to-Digital Conversion (ADC) & Dynamic Range 1.7 Instrument Optical & Fluidic Troubleshooting

2 Chapter 2: Panel & Experiment Design

2.1 Sample Collection, Anticoagulants, Integrity & Stability 2.2 Sample Preparation Protocols: Lyse-No-Wash, Lyse-Wash & Permeabilization 2.3 Cell Enrichment & Isolation Methods 2.4 Fluorochrome Properties, Laser Excitation, Emission Spectra & Tandem Dyes 2.5 Compensation Theory & Spectral Overlap Spreading 2.6 Experimental Controls: FMO, Isotype, Viability & Biological Controls 2.7 Panel Design Architecture & Antigen Density Matching

3 Chapter 3: Clinical Diagnostic Immunophenotyping

3.1 Hematolymphoid Differentiation & Gating Baselines 3.2 Chronic Lymphocytic Leukemia (CLL) & Mature B-Cell Lymphomas 3.3 Plasma Cell Neoplasms & Monoclonal Gammopathies 3.4 Acute Myeloid Leukemia (AML) & Lineage Assignment 3.5 Acute Lymphoblastic Leukemia (B-ALL & T-ALL) Subtyping 3.6 Minimal/Measurable Residual Disease (MRD) Detection 3.7 Primary Immunodeficiencies & Immune Monitoring

4 Chapter 4: Special & Emerging Applications

4.1 Cell Function, Proliferation & Apoptosis Assays 4.2 Multiplex Bead Arrays & Soluble Analyte Quantification 4.3 Solid Organ Transplant & HLA Crossmatching 4.4 Stem Cell Enumeration & ISHAGE Protocol 4.5 Cell Cycle & DNA Content Analysis 4.6 Rare Event & Small Particle (Extracellular Vesicle) Analysis 4.7 Fetal Hemoglobin Assay & Fetomaternal Hemorrhage 4.8 Preparative Cell Sorting: Electrostatic Droplet Deflection & Microfluidics 4.9 Imaging Flow Cytometry: Multispectral Imaging & Spatial Localization 4.10 Mass Cytometry (CyTOF) & Single-Cell Elemental Analysis

5 Chapter 5: Data Analysis, Informatics & High-Dimensional Cytometry

5.1 Data Standards, FCS File Format (FCS 2.0/3.0/3.1) & Metadata 5.2 Data Display & Scaling Transformations (Log, Bi-exponential, Hyperlog, ArcSinh) 5.3 Gating Hierarchy & Population Isolation Strategies 5.4 High-Dimensional Data Reduction (t-SNE, UMAP, PCA) & Automated Clustering 5.5 Common Data Modeling & Population Comparison Metrics 5.6 Quantitative Calibration & Molecules of Equivalent Soluble Fluorochrome (MESF) 5.7 Data Analysis Artifacts & Data Troubleshooting

6 Chapter 6: Quality Control, Quality Assurance & Laboratory Administration

6.1 Daily Quality Control, CS&T Beads & Performance Tracking 6.2 Assay Validation & Verification Standards (CLSI H42-A2, H62) 6.3 Biosafety & Aerosol Containment in Flow Cytometry 6.4 Laboratory Administration, Regulatory Compliance (CLIA, CAP, FDA) & Personnel 6.5 Reagent Qualification, Titration & Stability Testing 6.6 Clinical Correlation & Multidisciplinary Reporting

4.4 Stem Cell Enumeration & ISHAGE Protocol

Key Takeaways Explain This Topic AI

The ISHAGE (International Society of Hematotherapy and Graft Engineering) protocol enumerates CD34+ cells by sequential gating: bright CD45, then CD34+ with low SSC, then a viability gate, on a counting-bead or dual-platform basis.

Single-platform counting uses known-number fluorescent beads to derive absolute CD34+ cells per microliter without a separate hematology analyzer; dual-platform combines flow percent with a CBC count.

CD34+ stem cells are CD45 dim (not negative) with low side scatter; confusing them with bright CD45 blasts or platelet debris is a common enumeration error.

Viability (7-AAD exclusion) and accurate CD34+ percent are critical because the CD34+ cell dose (cells/kg recipient) drives hematopoietic engraftment decisions.

Last updated: July 2026

4.4 Stem Cell Analysis (CD34 Enumeration)

CD34 is the canonical hematopoietic progenitor marker. Accurate CD34+ cell dose (cells per kilogram recipient body weight) predicts engraftment after autologous and allogeneic transplant, so enumeration is a regulated, high-stakes flow assay.

The ISHAGE Protocol

The International Society of Hematotherapy and Graft Engineering (ISHAGE) single-platform method is the reference. It uses sequential gating on a CD45/CD34 plot:

Total CD45+ events (all leukocytes) — gate on bright CD45 to exclude debris and platelets.

CD34+ with low SSC — from the CD45+ gate, identify CD34-positive, low-side-scatter events.

Refine CD45 dim — true CD34+ progenitors are CD45 dim , not CD45 negative; a bivariate CD45 vs SSC gate confirms the stem cell cluster (the "751" region in some implementations).

Viability gate — exclude 7-AAD+ (or other viability dye) dead cells from the CD34+ count.

Counting beads — known-number fluorescent beads added to a measured sample volume let you convert CD34+ event count to absolute cells per microliter (single platform).

Single-Platform vs Dual-Platform

Method Source of absolute count Pros / Cons

Single-platform Internal counting beads of known concentration Self-contained; avoids inter-instrument CBC variance; the ISHAGE standard

Dual-platform Flow % CD34+ × CBC WBC (from hematology analyzer) Uses existing equipment; sensitive to CBC error and sample timing

Single-platform is preferred because it does not depend on a second instrument; all the information (percent CD34+ and absolute count) is acquired in one tube with counting beads. The absolute count uses: target events / bead events × bead concentration, gated to the same acquisition volume.

Where Enumeration Goes Wrong

Bright CD45 vs CD45 dim. True CD34+ stem cells are CD45 dim; gating CD34+ only and ignoring CD45 leads to over-counting from platelet and debris CD34-nonspecific events.

Nonspecific binding / Fc block. Dead cells and monocytes bind nonspecifically; viability gating and Fc-receptor block (or CD14 exclusion) reduce false positives.

Platelet clumps and doublets. Count singlets by FSC-H vs FSC-A; doublets inflate apparent CD34+ events.

Sample type. Peripheral blood (mobilized with G-CSF, measured at the apheresis peak), apheresis product, bone marrow, and cord blood each have expected CD34+ ranges; a "stem cell mobilization" assessment predicts collection yield.

Mobilization and Collection

G-CSF mobilizes CD34+ cells from marrow into blood; the CD34+ count per microliter on the mobilization day predicts the apheresis yield. Poor mobilizers may receive plerixafor (a CXCR4 antagonist) to amplify release. The collection target is commonly ≥2–5 × 10⁶ CD34+ cells/kg recipient; below that, additional collection days or mobilization adjustments are considered. CD34 enumeration therefore feeds the decision to start, continue, or stop apheresis.

Clinical Decision

The CD34+ cell dose target (commonly ≥2–5 × 10⁶ CD34+ cells/kg for autologous, allogeneic thresholds vary) determines whether collection proceeds or continues. A poor mobilizer may need plerixafor augmentation. Post-thaw viability and CD34+ recovery also enter release decisions, since cryopreservation can reduce viable CD34+ content.

Worked Example: Single-Platform Absolute Count

A 100 µL sample is stained and acquired with 50 µL of counting beads at a known concentration of 10,000 beads/µL (so 500,000 beads total in the tube, but the relevant quantity is the bead concentration). The cytometer records 4,000 CD34+ events and 50,000 bead events in the acquired fraction. Because the bead-to-cell ratio is preserved across the acquired fraction, absolute CD34+ cells per µL = (CD34+ events / bead events) × bead concentration = (4,000 / 50,000) × 10,000 = 800 CD34+ cells/µL. Multiply by the apheresis-product volume and divide by recipient weight to get the dose in cells/kg. A common error is to skip the bead-event gate or to use a different sample-to-bead volume than the protocol specifies, which corrupts the ratio.

Linearity and Validation

Enumeration assays are validated for linearity across the expected range (low to high CD34+ counts), with acceptance criteria for intra-assay and inter-assay precision. Low-level samples are run in duplicate or triplicate because Poisson counting error dominates at few events: the relative SD of a count of N is roughly √N / N, so at least 100 target events are needed for a <10% counting CV.

Exam Traps

CD34+ stem cells are CD45 dim , not CD45 negative.

ISHAGE uses sequential gating (CD45 → CD34/SSC → viability), not a single CD34 histogram.

Single-platform uses counting beads; dual-platform relies on a CBC.

7-AAD excludes dead cells from the CD34 count; without viability gating, dead-cell nonspecific binding inflates the count.